Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis.
We assessed the role of leukotrienes (LTs) in Munich-Wistar rats with passive Heymann nephritis (PHN), an animal model of human membranous nephropathy. 10 d after injection of anti-Fx1A antibody, urinary protein excretion rate (Upr) in PHN was significantly higher than that of control. Micropuncture studies demonstrated reduced single nephron plasma flow and glomerular filtration rates, increased transcapillary hydraulic pressure difference, pre- and postglomerular resistances, and decreased ultrafiltration coefficient in PHN rats. Glomerular LTB4 generation from PHN rats was increased. Administration of the 5-LO activating protein inhibitor MK886 for 10 d markedly blunted proteinuria and normalized glomerular hemodynamic abnormalities in PHN rats. An LTD4 receptor antagonist SK&F 104353 led to an immediate reduction in Upr and to reversal of glomerular hemodynamic impairment. Ia(+) cells/glomerulus were increased in PHN rats. In x-irradiated PHN rats, which developed glomerular macrophage depletion, augmented glomerular LT synthesis was abolished. Thus, in the autologous phase of PHN, LTD4 mediates glomerular hemodynamic abnormalities and a hemodynamic component of the accompanying proteinuria. The synthesis of LTD4 likely occurs directly from macrophages or from macrophage-derived LTA4, through LTC4 synthase in glomerular cells.
Department of Medicine, Emory University, Atlanta, Georgia 30033.
T
T
Katoh
E A
EA
Lianos
M
M
Fukunaga
K
K
Takahashi
K F
KF
Badr
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D002452:Cell Count; D003998:Dicarboxylic Acids / Q000494:pharmacology; D015433:Glomerulonephritis, Membranous / Q000097:blood / Q000503:physiopathology*; D006439:Hemodynamics; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D007150:Immunohistochemistry; D007211:Indoles / Q000494:pharmacology; D007668:Kidney / Q000502:physiology; D007678:Kidney Glomerulus / Q000098:blood supply / Q000166:cytology; D020024:Leukotriene Antagonists; D008084:Lipoxygenase / Q000494:pharmacology; D008264:Macrophages / Q000166:cytology; D008297:Male; D011507:Proteinuria / Q000378:metabolism / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000502:physiology*; D012756:Sheep / Q000276:immunology; D002722:Chlorobenzenes
D000888:Antibodies, Anti-Idiotypic; D003998:Dicarboxylic Acids; D000949:Histocompatibility Antigens Class II; D007211:Indoles; D020024:Leukotriene Antagonists; D008084:Lipoxygenase; D013189:SRS-A; C048844:anti-IgG; C060893:MK-886; D002722:Chlorobenzenes; C052393:pobilukast